Andreas H. Diacon

Task Applied Science — South Africa

Medicine · Health Sciences

58h-index13.0kcitations263works8.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Tuberculosis Research and Epidemiology(152), Mycobacterium research and diagnosis(68), Infectious Diseases and Tuberculosis(34), Lung Cancer Diagnosis and Treatment(32), Pneumonia and Respiratory Infections(31)

Publications260 total

Clinical testing of drug treatment shortening in patients with TB using PET/CT imaging of lung lesions
Science Translational Medicine·2026· 1 citedOpen Access
Effect of HIV on bedaquiline and delamanid pharmacokinetics in patients with multidrug-resistant TB
The International Journal of Tuberculosis and Lung Disease·2025
Cerebrospinal fluid penetration of cycloserine/terizidone and clofazimine in patients with pulmonary TB
Antimicrobial Agents and Chemotherapy·2025Open Access
Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV
UNC Libraries·2025Open Access
Bridging to Paediatric Dosing: Relative Bioavailability of Suspended Rifapentine and Isoniazid in an Open-Label Randomized Trial in Adults on Tuberculosis Preventive Therapy
Clinical Pharmacokinetics·2025Open Access
Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV
Nature Communications·2025· 1 citedOpen Access
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB
Journal of Antimicrobial Chemotherapy·2025· 2 citedOpen Access
A Phase 2a Study of the Early Bactericidal Activity of Rifampicin in Combination With Meropenem Plus Amoxicillin/Clavulanate Among Adults With Rifampicin-Resistant Pulmonary Tuberculosis
Clinical Infectious Diseases·2025Open Access
Quantification of bactericidal activity using the PATHFAST TB LAM Ag assay during the first 14 days of pulmonary tuberculosis treatment
Frontiers in Antibiotics·2025· 4 citedOpen Access
Author Correction: Risk-stratified treatment for drug-susceptible pulmonary tuberculosis
Nature Communications·2025Open Access
Telacebec, a Potent Agent in the Fight against Tuberculosis: Findings from a Randomized, Phase 2 Clinical Trial and Beyond
American Journal of Respiratory and Critical Care Medicine·2025· 9 citedOpen Access
Efficacy and Safety of Higher Doses of Levofloxacin for Multidrug-resistant Tuberculosis: A Randomized, Placebo-controlled Phase II Clinical Trial
American Journal of Respiratory and Critical Care Medicine·2025· 7 citedOpen Access
Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial
The Lancet Infectious Diseases·2025· 18 cited
Tuberculosis: An Update for the Clinician
Respirology·2025· 21 citedOpen Access
Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study
UNC Libraries·2025Open Access
Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study
EClinicalMedicine·2025· 5 citedOpen Access
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043–02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial
The Lancet Microbe·2025· 16 citedOpen Access
Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study
PLOS Global Public Health·2024· 3 citedOpen Access
Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial
The Lancet Infectious Diseases·2024· 8 citedOpen Access
Risk-stratified treatment for drug-susceptible pulmonary tuberculosis
Nature Communications·2024· 21 citedOpen Access
page 1 of 13Next →

Frequent Co-authors

Rodney Dawson(19), Amour Venter(15), Peter R. Donald(13), Florian von Groote-Bidlingmaier(8), Stephen H. Gillespie(8), Martin J. Boeree(7), Coenraad F.N. Koegelenberg(7), Christo van Niekerk(6), Carl M. Mendel(6), Patrick Phillips(6), Melvin Spigelman(5), Gerhard Walzl(5), Norbert Heinrich(5), Rob E. Aarnoutse(5), Kim Narunsky(5), Chris T. Bolliger(5), Alexander S. Pym(4), R. F. Patientia(4), Tine De Marez(4), Koen Andries(4)